Obinutuzumab binds CD20 on B cells; its Fc engages Fcγ receptors (primarily CD16a on NK cells, and can engage CD16b on neutrophils) to mediate ADCC/phagocytosis against CD20+ cells. CD16b-expressing cells are effector cells, not targets, and are not directly killed.